STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 201–300 of 1,004
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
Perrier, A., Didelot, A., Laurent‐Puig, P., Blons, H., & Garinet, S. (2020) · Biomolecules · doi:10.3390/biom10071061 · Cited by 111
“STK11/LKB1-inactivating mutations have been linked to a primary resistance to PD-1 inhibitors [147].”
BackgroundRNA-based therapies: A cog in the wheel of lung cancer defense
Κhan, P., Siddiqui, J. A., Lakshmanan, I., Ganti, A. K., Salgia, R., Jain, M., Batra, S. K., & Nasser, M. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01338-2 · Cited by 110
Kim, Y., Kim, C. H., Lee, H. Y., Lee, S., Kim, H. S., Lee, S., Cha, H., Hong, S., Kim, K., Seo, S. W., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.033 · Cited by 102
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Pavan, A., Attili, I., Pasello, G., Guarneri, V., Conte, P., & Bonanno, L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0690-1 · Cited by 104
“Skoulidis and colleagues recently demonstrated that KRASmutant lung adenocarcinomas harboring LKB1 comutations are associated with lower progression free survival (PFS) and OS to Protein death 1 (PD-1) blockade, thus suggesting a role of LKB1 in primary resistance to this class of drugs [41].”
BackgroundLi, R., Salehi‐Rad, R., Crosson, W. P., Momcilovic, M., Lim, R. J., Ong, S. L., Huang, Z. L., Zhang, T.-H., Abascal, J. W., Dumitras, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3564 · Cited by 105
Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97
Self-citationDirect Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Reita, D., Pabst, L., Pencreach, E., Guérin, E., Dano, L., Rimelen, V., Voegeli, A.-C., Vallat, L., Mascaux, C., & Beau-Faller, M. (2022) · Cancers · doi:10.3390/cancers14051321 · Cited by 95
Pan-cancer proteogenomics characterization of tumor immunity
Petralia, F., Ma, W., Yaron, T. M., Caruso, F. P., Tignor, N. L., Wang, J. M., Charytonowicz, D., Johnson, J. L., Huntsman, E. M., Marino, G. B., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.027 · Cited by 113
Self-citationWang, X., Lamberti, G., Federico, A. D., Alessi, J. V., Ferrara, R., Sholl, M. L., Awad, M. M., Vokes, N. I., & Ricciuti, B. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.007 · Cited by 115
Self-citationPlant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites
Teng, Y., Luo, C., Qiu, X., Mu, J., Sriwastva, M. K., Xu, Q., Liu, M., Hu, X., Xu, F., Zhang, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56498-2 · Cited by 119
“Given that PD-1/PD-L1 blockade is primarily involved in the last step, any abnormalities in the previous steps may affect the ef fi cacy of PD-L1 therapy and lead to resistance 83,84 .”
Berland, L., Heeke, S., Humbert, O., Macocco, A., Long-Mira, E., Lassalle, S., Lespinet-Fabre, V., Lalvée, S., Bordone, O., Cohen, C., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.11.102 · Cited by 95
Della Corte, C. M., Barra, G., Ciaramella, V., Di Liello, R., Vicidomini, G., Zappavigna, S., Luce, A., Abate, M., Fiorelli, A., Caraglia, M., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1257-1 · Cited by 95
“[23], including the KRAS/LKB1 mutated patients that represent an intrinsically resistant group to anti-PD-1/PD-L1 immunotherapies, with low immune and inflammatory marker Fig.”
BackgroundPérez-Johnston, R., Araújo-Filho, J. D. A. B., Connolly, J. G., Caso, R., Whiting, K. A., Tan, K. S., Zhou, J. H., Gibbs, P., Rekhtman, N., Ginsberg, M. S., et al. (2022) · Radiology · doi:10.1148/radiol.211582 · Cited by 108
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 101
Updated Prognostic Factors in Localized NSCLC
Garinet, S., Wang, P., Mansuet‐Lupo, A., Fournel, L., Wislez, M., & Blons, H. (2022) · Cancers · doi:10.3390/cancers14061400 · Cited by 108
“It is a generally accepted biomarker of primary resistance to ICI in KRAS-mutated NSCLC [96].”
BackgroundUnveiling the role of KRAS in tumor immune microenvironment
Xu, M., Zhao, X., Wen, T., & Qu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116058 · Cited by 102
Base editing screens map mutations affecting interferon-γ signaling in cancer
Coelho, M. A., Cooper, S., Strauß, M. E., Karakoç, E., Bhosle, S. G., Gonçalves, E., Picco, G., Burgold, T., Cattaneo, C. M., Veninga, V., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.009 · Cited by 102
Trefny, M. P., Kaiser, M., Stanczak, M. A., Herzig, P., Savic, S., Wiese, M. N., Lardinois, D., Laubli, H. P., Uhlenbrock, F., & Zippelius, A. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02558-z · Cited by 89
Advances in the Treatment of Non–Small Cell Lung Cancer
Patel, S. A., & Weiss, J. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.010 · Cited by 97
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 122
“Mutations in tumour suppressor genes such as STK11 and KEAP1 are linked to an immuno-suppressive TME and poor responses to ICI 190,192,193 .”
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
“The tumor suppressor TP53 mutation, a well-known negative prognostic factor in lung cancer, is found to be associated with increased PD-L1 expression and higher TMB in non-squamous NSCLC (30) and KRAS-mutated lung adenocarcinoma (51).”
BackgroundResultPore, N., Wu, S., Standifer, N., Jure-Kunkel, M., de los Reyes, M., Shrestha, Y., Halpin, R., Rothstein, R., Mulgrew, K., Blackmore, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1543 · Cited by 88
“These alterations, found in approximately 5–30% of patients with NSCLC (4–8), have been associated with lack of response to nivolumab, both as monotherapy or in combination with ipilimumab (2, 4), and lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy (9).”
BackgroundResultInfluentialImmunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou, S., & Yang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1129465 · Cited by 122
“In KRASmutant lung adenocarcinoma, STK11 mutation was identified as the most common genomic background for primary resistance to PD-1/PD-L1 inhibitors (46).”
BackgroundExploiting temporal aspects of cancer immunotherapy
Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 105
“…deletions 76 ), disruptive IFNγ signalling (such as JAK1 or JAK2 mutations 77 ), T cell exclusion (such as serine–threonine kinase 11 ( STK11 ) or Kelch-like ECH-associated protein 1 ( KEAP1 ) mutations 78 ) or impaired tumour immune cell infiltration (such as mutations in the WNT pathway 79 ).”
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yuan, Y. J., Adam, A., Zhao, C., & Chen, H. (2021) · Cancers · doi:10.3390/cancers13040663 · Cited by 92
“Different subgroups of KRAS-mutant LUAD are dependent on STK11/LKB1 or TP53 mutations, and alterations of the former has been confirmed as a major factor that leads to primary resistance to PD-1 blockade [54].”
BackgroundHerzog, B. H., Baer, J. M., Borcherding, N. C., Kingston, N. L., Belle, J. I., Knolhoff, B. L., Hogg, G. D., Ahmad, F. F., Kang, L., Petrone, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8005 · Cited by 103
Expósito, F., Redrado, M., Houry, M., Hastings, K., Molero-Abraham, M., Lozano, T., Solórzano, J. L., Sanz‐Ortega, J., Adradas, V., Amat, R., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3023 · Cited by 102
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 100
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
Shire, N. J., Klein, A. B., Golozar, A., Collins, J. M., Fraeman, K. H., Nordstrom, B. L., McEwen, R., Hembrough, T., & Rizvi, N. A. (2020) · PLOS ONE · doi:10.1371/journal.pone.0238358 · Cited by 85
“The authors of the study conclude that the effect likely extends to the entire nonsquamous NSCLC population, regardless of KRAS status [19].”
BackgroundMethodInfluentialRedín, E., Garmendia, I., Lozano, T., Serrano, D., Senent, Y., Redrado, M., Villalba-Esparza, M., de Andrea, C. E., Expósito, F., Ajona, D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001496 · Cited by 90
“29 30 On the contrary, concurrent KRAS-TP53 mutations are associated with infiltration of effector CD8+ T lymphocytes and responsiveness to anti-PD-1 therapy.”
BackgroundPishvaian, M. J., Blais, E. M., Bender, R. J., Rao, S., Boca, S. M., Chung, V. M., Hendifar, A. E., Mikhail, S., Sohal, D. P. S., Pohlmann, P. R., et al. (2019) · JAMIA Open · doi:10.1093/jamiaopen/ooz045 · Cited by 94
“We also recognize that the scoring models for ranking cancer treatments will evolve with new discoveries of biomarkers and treatments, especially those involving combinations of immuno-oncology, targeted and chemotherapeutic agents and the need to address emerging evidence for markers of possible resistance that are c…”
BackgroundGuo, L., Wei, R., Lin, Y., & Kwok, H. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01508 · Cited by 89
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Passiglia, F., Cappuzzo, F., Alabiso, O., Bettini, A. C., Bidoli, P., Chiari, R., Defferrari, C., Delmonte, A., Finocchiaro, G., Francini, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0234-3 · Cited by 81
Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice
Hicks, J. K., Aquilante, C. L., Dunnenberger, H. M., Gammal, R. S., Funk, R. S., Aitken, S. L., Bright, D. R., Coons, J. C., Dotson, K. M., Elder, C. T., et al. (2019) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1118 · Cited by 92
“A multitude of evidence, rather than a single RCT, will likely be needed to demonstrate the value of clinical pharmacogenomics.(86) Such evidence will also be essential in expanding reimbursement models and advancing the roles and responsibilities of clinical pharmacists in pharmacogenomics.”
BackgroundSelf-citationRich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M. S., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4049 · Cited by 85
Domblides, C., Rochefort, J., Riffard, C., Panouillot, M., Lescaille, G., Teillaud, J., Mateo, V., & Dieu‐Nosjean, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698604 · Cited by 88
Salehi‐Rad, R., Li, R., Paul, M. K., Dubinett, S. M., & Liu, B. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.003 · Cited by 94
Peng, L., Qin, B., Xiao, K., Xu, S., Yang, J., Zang, Y., Stebbing, J., & Xie, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1781333 · Cited by 89
“3%), which was reported previously to affect efficacy of ICI.(41,42) Therefore, in NSCLC patients receiving atezolizumab, different clinicpathologic features including tumor mutation profiles may explain the ethnic differences of efficacy though we are unaware of an “Asian signature”.”
BackgroundInfluentialImmunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
Seegobin, K., Majeed, U., Wiest, N. E., Manochakian, R., Lou, Y., & Zhao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750657 · Cited by 89
“The correlation between STK11/LKB1 genomic alterations and the efficacy of ICI treatment in KRAS mutant NSCLC was also evaluated using the Stand Up To Cancer (SU2C) dataset (13).”
BackgroundMethodLee, J. W., Zhang, Y., Eoh, K. J., Sharma, R., Sanmamed, M. F., Wu, J., Choi, J., Park, H. S., Iwasaki, A., Kaftan, E., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.004 · Cited by 80
Self-citationPeters, S., Cho, B. C., Luft, A. V., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Trukhin, D., Kim, S.-W., Ursol, G. M., Hussein, M., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1381 · Cited by 78
Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
Adashek, J. J., Kato, S., Ferrara, R., Russo, G. L., & Kurzrock, R. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0636 · Cited by 104
“There are also several markers of tumor resistance, again of genomic origin: (A) STK11 and KRAS co-mutations in lung cancer [55]; (B) loss-of-function mutations in the genes encoding interferon-receptor–associated Janus kinase 1 or Janus kinase 2, concurrent with deletion of the wild-type allele [56]; and (C) truncati…”
BackgroundReal world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Cui, W., Franchini, F., Alexander, M., Officer, A., Wong, H.-L., IJzerman, M., Desai, J., & Solomon, B. J. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.030 · Cited by 75
“[38,39] Exploring combinations of KRASG12C targeting agents with checkpoint inhibitors, and upfront use of this combination, may be one method to Fig.”
MethodFriedman, C. F., Snyder, A., Zhou, Q. C., Carducci, M. A., de Meritens, A. B., Corr, B. R., Fu, S., Hollmann, T. J., Iasonos, A. E., Konner, J. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001126 · Cited by 85
Yang, Y., Zhang, H., Huang, S., & Chu, Q. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020709 · Cited by 84
“STK11/LKB1 mutations have been found to cause primary resistance to PD-1/PD-L1 inhibitors in patients with KRAS-mutated lung adenocarcinoma [122].”
BackgroundMok, T. S. K., Lopes, G., Cho, B. C., Kowalski, D. M., Kasahara, K., Wu, Y.-L. L. C., de Castro, G., Turna, H. Z., Cristescu, R., Aurora-Garg, D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.011 · Cited by 88
Bao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 88
Saleh, M. M., Scheffler, M., Merkelbach‐Bruse, S., Scheel, A. H., Ulmer, B., Wolf, J., & Buettner, R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.764 · Cited by 96
Preet, R., Islam, M. A., Shim, J., Rajendran, G., Mitra, A., Vishwakarma, V., Kutz, C., Choudhury, S., Pathak, H. B., Dai, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58553-4 · Cited by 97
Self-citationKRAS in NSCLC: State of the Art and Future Perspectives
Cascetta, P., Marinello, A., Lazzari, C., Gregorc, V., Planchard, D., Bianco, R., Normanno, N., & Morabito, A. (2022) · Cancers · doi:10.3390/cancers14215430 · Cited by 76
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
Gstalder, C., Liu, D., Miao, D., Lutterbach, B. A., DeVine, A. L., Lin, C., Shettigar, M., Pancholi, P., Buchbinder, E. I., Carter, S. L., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1416 · Cited by 78
“Recent studies demonstrated that inactivation of the tumor suppressor STK11/LKB1 decreases STING expression and dsDNA sensing (45), while the loss of Stk11/Lkb1 in tumor cells promotes resistance to PD-1 blockade (12).”
BackgroundRoss, J. S., Sokol, E. S., Moch, H., Mileshkin, L., Baciarello, G., Losa, F., Beringer, A., Thomas, M., Elvin, J. A., Ngo, N., et al. (2020) · The Oncologist · doi:10.1002/onco.13597 · Cited by 81
“%) patients, although such alterations have been observed to be enriched in thyroid transcription factor-1 IHC-negative NSCLC [39], suggesting that these specimens may represent NSCLC not detected by the computed tomography scan.”
BackgroundSelf-citationOvercoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS
Kitajima, S., Asahina, H., Chen, T., Guo, S., Quiceno, L. G., Cavanaugh, J. D., Merlino, A. A., Tange, S., Terai, H., Kim, J. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.009 · Cited by 75
“For example, KRAS;TP53mutant (KP) orKRAS;LKB1mutant (KL) NSCLC cells exhibit divergent gene expression profiles and sensitivity to targeted or immune directed therapies (Kottakis et al., 2016; Koyama et al., 2016; Skoulidis et al., 2018).”
Self-citationBange, E., Marmarelis, M. E., Hwang, W.-T., Yang, Y.-X., Thompson, J. C., Rosenbaum, J., Bauml, J. M., Ciunci, C., Alley, E. W., Cohen, R. B., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00326 · Cited by 74
“1 v 16 months for KRAS/STK11 v KRAS v KRAS/TP53, respectively).(12)”
BackgroundTherapeutics Targeting Mutant KRAS
Thein, K. Z., Biter, A. B., & Hong, D. S. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-033145 · Cited by 72
Spahn, S., Roessler, D., Pompilia, R., Gabernet, G., Gladstone, B. P., Horger, M., Biskup, S., Feldhahn, M., Nahnsen, S., Hilke, F. J., et al. (2020) · Cancers · doi:10.3390/cancers12123830 · Cited by 79
“Mutations in cancers other than HCC associated with a negative outcome for ICI treatment include inactivating mutations in JAK1/2 [23] or beta-2-microglobulin in melanoma [24], MDM4 amplifications, r EGFR alt rations in different stage IV tumors [25] or STK11/LKB1 alter tions in KRAS-mutant lung adenocarcinoma [26].”
BackgroundKRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 74
“7% (showing better efficacy), respectively (27).”
Wu, C.-C., Wang, Y., Livingston, J. A., Zhang, J., & Futreal, P. A. (2022) · Nature Communications · doi:10.1038/s41467-021-27651-4 · Cited by 86
Self-citationTreatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
O’Sullivan, É., Keogh, A., Henderson, B., Finn, S. P., Gray, S. G., & Gately, K. A. (2023) · Cancers · doi:10.3390/cancers15061635 · Cited by 92
“, PD-L1) if KEAP1 is co-mutated, correlating to resistance to PD1 blockade in KRAS-mutated lung adenocarcinoma [22].”
BackgroundBurnett, G. L., Yang, Y. C., Aggen, J. B., Pitzen, J., Gliedt, M. K., Semko, C. M., Marquez, A., Evans, J. W., Wang, G., Won, W. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01658 · Cited by 72
Self-citationPalma, G., Khurshid, F., Lu, K., Woodward, B., & Husain, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00237-5 · Cited by 72
Peng, D. H., Rodriguez, B. L., Diao, L., Gaudreau, P.-O., Padhye, A., Konen, J. M., Ochieng, J. K., Class, C. A., Fradette, J. J., Gibson, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22875-w · Cited by 72
Self-citationDrugging the Undruggable: Advances on RAS Targeting in Cancer
Molina-Arcas, M., Samani, A., & Downward, J. (2021) · Genes · doi:10.3390/genes12060899 · Cited by 71
“While these data are exploratory, it is known that STK11mutated tumours have a poor response to immunotherapy [90] and KRYSTAL-1 data open the possibility of a biomarker-driven effect in this difficult-to-treat subgroup.”
BackgroundUlas, E. B., Dickhoff, C., Schneiders, F. L., Senan, S., & Bahce, I. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100244 · Cited by 76
“Volume 6 - Issue 5 - 2021 alterations such as STK11 mutations have been associated with resistance to anti-PD-(L)1 agents.(36) Such patient subgroups may be less likely to respond to ICIs, while suffering the risks of immune-related AEs.”
BackgroundKRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
Gao, G., Liao, W., Ma, Q., Zhang, B., Chen, Y., & Wang, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.004 · Cited by 71
Park, S., Olsen, S., Ku, B. M., Lee, M., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Park, K., Choi, Y., et al. (2021) · Cancer · doi:10.1002/cncr.33571 · Cited by 80
“An assessment of PD- L1 expression, a biomarker of potential immunotherapy sensitivity, is also recommended,(3) along with genomic alterations that act as negative biomarkers to suggest avoiding specific therapeutics, such as in the case of STK11 or MDM2 mutations, which may affect tumor responses to immune checkpoint…”
BackgroundScalera, S., Mazzotta, M., Corleone, G., Sperati, F., Terrenato, I., Krasniqi, E., Pizzuti, L., Barba, M., Vici, P., Gallo, E., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.010 · Cited by 80
Han, J. H., Kim, Y. K., Kim, H., Lee, J., Oh, M. J., Kim, S. B., Kim, M., Kim, K. H., Yoon, H. J., Lee, M., et al. (2022) · 癌症:英文版 · doi:10.1002/cac2.12332 · Cited by 78
“Although immunotherapy is ineffective in KL tumors [8], combination treatment with CAMKK2 inhibitors might overcome the resistance via cancer cell autonomous suppression of EMT programs as well as activation of CD8+ T cells in the tumor microenvironment based on a recent report indicating that CAMKK2 signaling in tumo…”
BackgroundInfluentialSelf-citationMin, H., Jang, H.-J., Park, K. H., Hyun, S. Y., Park, S. J., Kim, J. H., Son, J., Kang, S. S., & Lee, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2041-z · Cited by 78
Araujo, H. A., Pechuan-Jorge, X., Zhou, T., Do, M. T., Hu, X., Rojas Alvarez, F. R., Salvatierra, M. E., Ibarguen, H. P., Lee, R., Raghulan, R., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0421 · Cited by 70
Self-citationZhang, C., Zhang, G., Sun, N., Zhang, Z., Zhang, Z., Luo, Y., Che, Y., Xue, Q., & He, J. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102959 · Cited by 77
“Besides, two subtypes of LUAD—EGFR MUT patients and STK11/ LKB1 and KRAS co-MUT patients—are reported to have a low response to immune checkpoint inhibitors [33,34].”
BackgroundTargeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 70
“Interestingly, some evidence supports the hypothesis that STK11/ LKB1 co-mutation in KRAS mutated NSCLC could represent a negative predictive factor for immunotherapy (144).”
Rangel, M., Kong, J., Bhatt, V. D., Khayati, K., & Guo, J. Y. (2021) · FEBS Journal · doi:10.1111/febs.16125 · Cited by 82
Role of DNA repair defects in predicting immunotherapy response
Zhang, J., Shih, D. J. H., & Lin, S.-Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00202-7 · Cited by 69
Self-citationZhu, L., Liu, J., Chen, J., & Zhou, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01218-8 · Cited by 84
“A clinical trial reported that STK11/LKB1 mutations, the most prevalent genomic driver of PD-1 blockade resistance, are negatively related to therapy in KRASmutant lung adenocarcinoma [53].”
BackgroundBai, X., Guo, Z.-Q., Zhang, Y.-P., Fan, Z., Liu, L., Liu, L., Long, L.-L., Ma, S.-C., Wang, J., Fang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36892-4 · Cited by 73
Self-citationYang, Y., Liu, H., Chen, Y., Xiao, N., Zheng, Z., Liu, H., & Wan, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05757-5 · Cited by 78
“Interestingly, mutations in STK11 are usually correlated with mutations in KRAS [108], and STK11/KRAS comutations have been reported to lead to worse survival outcomes in patients treated with ICI [109], in support of a predictive role for this co-mutation.”
BackgroundPulanco, M. C., Madsen, A. T., Tanwar, A., Corrigan, D. T., & Zang, X. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01019-8 · Cited by 74
“Mutations in the tumor suppressor STK11/LKB1 in NSCLC are associated with TIL exclusion from the TME and primary resistance to PD-1 blockade [138, 156].”
BackgroundNadal, E., Saleh, M. N., Ponce-Aix, S., Ochoa-de-Olza, M., Patel, S. P., Antonia, S. J., Zhao, Y., Gueorguieva, I., Man, M. Z., Estrem, S. T., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11153-1 · Cited by 78
Konen, J. M., Wu, H., & Gibbons, D. L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.04.006 · Cited by 82
Blons, H., Garinet, S., Laurent‐Puig, P., & Oudart, J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.48 · Cited by 76
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
Lantuéjoul, S., Damotte, D., Hofman, V., & Adam, J. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.103 · Cited by 69
“Neutrophils enriched tumors are significantly associated with STK11/LKB1 and KEAP1 mutations, a low PD-L1 expression, a low T-cell infiltration, and a primary resistance to PD-1 inhibitors (9-11).”
BackgroundSelenica, P., Alemar, B., Matrai, C. E., Talia, K. L., Veras, E. F. T., Hussein, Y. R., Oliva, E., Beets‐Tan, R. G. H., Mikami, Y., McCluggage, W. G., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-00726-1 · Cited by 71
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Qian, J., Nie, W., Lü, J., Zhang, L., Zhang, Y., Zhang, B., Wang, S., Hu, M., Xu, J., Lou, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32717 · Cited by 69
“Furthermore, STK11 alterations in KRAS-mutant lung adenocarcinoma were identified as a major driver of primary resistance to a checkpoint inhibitor.(30) In agreement with these previous findings, the current study showed that STK11 mutations were related to an inferior response to atezolizumab.”
ResultPredictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond
Uruga, H., & Mino-Kenudson, M. A. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03030-8 · Cited by 73
Self-citationUnderstanding genomics and the immune environment of penile cancer to improve therapy
Aydın, A. M., Chahoud, J., Adashek, J. J., Azizi, M., Magliocco, A. M., Ross, J. S., Necchi, A., & Spiess, P. E. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0359-z · Cited by 70
Self-citationMuto, S., Enta, A., Maruya, Y., Inomata, S., Yamaguchi, H., Mine, H., Takagi, H., Ozaki, Y., Watanabe, M., Inoue, T., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11010190 · Cited by 73
“Thus, genomic aberrations in STK11/LKB1 have been reported to mediate a less-immunogenic-tumor microenvironment and be a major cause of resistance to anti-PD-1 antibody treatment in NSCLC patients [84].”
BackgroundSantarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
“Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.”
BackgroundLau, S. C. M., Fares, A. F., Le, L. W., Mackay, K. M., Soberano, S., Chan, S. W. S., Smith, E. C., Ryan, M. I., Tsao, M., Bradbury, P. A., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.015 · Cited by 67
Zhang, D., Ning, J., Okon, I. S., Zheng, X., Satyanarayana, G., Song, P., Xu, S., & Zou, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03793-7 · Cited by 72
Zhu, M., Kim, J., Deng, Q., Ricciuti, B., Alessi, J. V., Eglenen-Polat, B., Bender, M. E., Huang, H.-C., Kowash, R. R., Cuevas, I., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.006 · Cited by 71
Self-citationYoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 74
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
Passiglia, F., Galvano, A., Castiglia, M., Incorvaia, L., Calò, V., Listì, A., Mazzarisi, S., Perez, A., Gallina, G., Rizzo, S., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919839928 · Cited by 71
Finn, S. P., Addeo, A., Dafni, U., Thunnissen, E., Bubendorf, L., Madsen, L. B., Biernat, W., Verbeken, E., Hernandez-Losa, J., Marchetti, A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.016 · Cited by 63
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 89
“Primary resistance mechanisms include the absence and loss of tumor antigens 15 , alterations in the MHC processing pathway 16 , low T cell in fi ltration, enhanced expression of VEGFand immunosuppressive cytokines 17 and mutationsin STK11 (alsoknownas LKB1 ) 18 .”
BackgroundResultSherafat, N. S., Keshavarz, A., Mardi, A., Mohammadiara, A., Aghaei, M., Maleki, L. A., & Mohammadi, M. H. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01751-7 · Cited by 69
“…TMB, immune cell infiltration, and angi-ogenesis-related gene signatures achieved an area under the curve (AUC) of 0.70 for response prediction, significantly outperforming the predictive power of any individual bio-marker, and thus reinforcing the clinical value of multi-parameter profiling [228].”
InfluentialPrognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Bianco, A., Perrotta, F., Barra, G., Malapelle, U., Rocco, D., & Palma, R. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194931 · Cited by 68
“Scientific interest is now directed to understanding the mechanisms of response to immune checkpoint inhibitors (ICIs) and determining prognostic factors and biomarkers.”
BackgroundInfluentialRuíz-Patiño, A., Arrieta, O. G., Cardona, A. F., Martin, C. M., Raez, L. E., Zatarain-Barrón, Z. L., Barrón, F., Ricaurte, L., Bravo-Garzón, M. A., Mas, L. A., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13272 · Cited by 67
Tumor-Derived cGAMP Regulates Activation of the Vasculature
Campisi, M., Sundararaman, S. K., Shelton, S. E., Knelson, E. H., Mahadevan, N. R., Yoshida, R., Tani, T., Ivanova, E., Cañadas, I., Osaki, T., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02090 · Cited by 62
“For example, KRAS mutant non-small cell lung cancers that inactivate the STK11/LKB1 tumor suppressor are strongly resistant to anti-PD-(L)1 therapy and exhibit T cell exclusion (4, 5).”
Background
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.